Key Highlights: Implications: By selling the Roorkee and Noida plants (for around ₹56 crore) but retaining brands, trademarks, its Beauty Entrepreneur network, and all commercial operation...
Key Highlights: Implications: Wegovy’s new MASH indication turns semaglutide into a dual liver–weight disease asset in India, opening a large, under-treated fatty liver market (about two i...
Key Highlights: Implications: Qdenga’s approval as India’s first dengue vaccine creates a new prevention market in a country where reported cases have risen about 11‑fold in two decad...
Key Highlights: Implications: Poviztra’s new MASH label lets Emcure plug innovator semaglutide directly into India’s emerging fatty liver treatment market, riding on ESSENCE data (63% stea...
Key Highlights: Implications: RPG Life Sciences is launching India’s first fixed-dose Naproxen + Esomeprazole tablet, Naprosyn ES, to enable safer long-term NSAID use by adding gastroprote...
Key Highlights: Implications: Viatris is selling up to 92 million Biocon shares (about 5.6% of the company) in a secondary sale, so Biocon gets no money from it; the deal is priced at a di...
Key Highlights: Implications: Emcure’s move to take Gennova to 100% ownership and fold it under the “One Emcure” framework tightens control over a strategically important biologi...
Key Highlights: Implications: The slump sale of Gennova’s small mRNA unit to Immunoscript for ₹139.5 crore effectively exits Emcure from a non-core, low-contribution bu...
Key Highlights: Implications: By reducing injections from 365 to 52 per year at near price parity, and potentially 20–25% lower annual treatment costs versus some analogue basals,&nbs...
Key Highlights: Implications: Pivot Path’s majority sale to an Ascent-led consortium effectively spins it out as an independent, PE-backed specialist, which should accelerate its growth in...
